Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation
Chuan Hong,Noel J Byrne,Beata Zamlynny,Srivanya Tummala,Li Xiao,Jennifer M Shipman,Andrea T Partridge,Christina Minnick,Michael J Breslin,Michael T Rudd,Shawn J Stachel,Vanessa L Rada,Jeffrey C Kern,Kira A Armacost,Scott A Hollingsworth,Julie A O'Brien,Dawn L Hall,Terrence P McDonald,Corey Strickland,Alexei Brooun,Stephen M Soisson,Kaspar Hollenstein
DOI: https://doi.org/10.1038/s41467-021-21087-6
2021-02-05
Abstract:Narcolepsy type 1 (NT1) is a chronic neurological disorder that impairs the brain's ability to control sleep-wake cycles. Current therapies are limited to the management of symptoms with modest effectiveness and substantial adverse effects. Agonists of the orexin receptor 2 (OX2R) have shown promise as novel therapeutics that directly target the pathophysiology of the disease. However, identification of drug-like OX2R agonists has proven difficult. Here we report cryo-electron microscopy structures of active-state OX2R bound to an endogenous peptide agonist and a small-molecule agonist. The extended carboxy-terminal segment of the peptide reaches into the core of OX2R to stabilize an active conformation, while the small-molecule agonist binds deep inside the orthosteric pocket, making similar key interactions. Comparison with antagonist-bound OX2R suggests a molecular mechanism that rationalizes both receptor activation and inhibition. Our results enable structure-based discovery of therapeutic orexin agonists for the treatment of NT1 and other hypersomnia disorders.